XBiotech Announces Addition of Dr. Dirk Arnold to its Scientific Advisory Board
March 23 2017 - 8:00AM
AUSTIN, Texas, March 23, 2017 (GLOBE
NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT) announced today that that
Dr. Dirk Arnold, a leading international specialist in
gastrointestinal (GI) cancers, has joined the Company's Scientific
Advisory Board (SAB). Dr. Arnold will work with XBiotech to help
navigate clinical development and communicate the findings for the
Company's lead product candidate in advanced colorectal cancer.
Dr. Arnold's main research interests include the treatment of
GI cancers with a focus on targeted and immunotherapies, among
others. Importantly, his special interest in clinical research
methodologies and benefit evaluation are relevant to one of
XBiotech's lead oncology programs, which has involved the
development of a novel measure of clinical efficacy in advanced
cancer patients.
Dr. Arnold is a member of the
following organizations: Executive Board of the European Society
for Medical Oncology (ESMO) and European Cancer Organization
(ECCO); chairman of Colorectal Cancer Study Group of the
German Society of Clinical Oncology (AIO); American Society of
Clinical Oncology (ASCO); Task Force Colorectal Cancer of the
European Organization for Research and Treatment of Cancer (EORTC)
GI study group; German Cancer Society; and the German Society of
Haematology and Medical Oncology (DGHO). He is
currently Director of the Insituto CUF de Oncologia in Lisbon,
Portugal.
About True Human(TM) Therapeutic
Antibodies
XBiotech's True Human(TM) antibodies are derived without
modification from individuals who possess natural immunity to
certain diseases. With discovery and clinical programs across
multiple disease areas, XBiotech's True Human antibodies have the
potential to harness the body's natural immunity to fight disease
with increased safety, efficacy and tolerability.
About XBiotech
XBiotech is a fully integrated global biosciences
company dedicated to pioneering the discovery, development and
commercialization of therapeutic antibodies based on its True
Human(TM) proprietary technology. XBiotech currently is advancing a
robust pipeline of antibody therapies to redefine the standards of
care in oncology, inflammatory conditions and infectious diseases.
Headquartered in Austin, Texas, XBiotech also is leading the
development of innovative biotech manufacturing technologies
designed to more rapidly, cost-effectively and flexibly produce new
therapies urgently needed by patients worldwide. For more
information, visit www.xbiotech.com.
Cautionary Note on
Forward-Looking Statements
This press release contains forward-looking statements, including
declarations regarding management's beliefs and expectations that
involve substantial risks and uncertainties. In some cases, you can
identify forward-looking statements by terminology such as "may,"
"will," "should," "would," "could," "expects," "plans,"
"contemplate," "anticipates," "believes," "estimates," "predicts,"
"projects," "intend" or "continue" or the negative of such terms or
other comparable terminology, although not all forward-looking
statements contain these identifying words. Forward-looking
statements are subject to inherent risks and uncertainties in
predicting future results and conditions that could cause the
actual results to differ materially from those projected in these
forward-looking statements. These risks and uncertainties are
subject to the disclosures set forth in the "Risk Factors" section
of certain of our SEC filings. Forward-looking statements are not
guarantees of future performance, and our actual results of
operations, financial condition and liquidity, and the development
of the industry in which we operate, may differ materially from the
forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Contact
Ashley Otero
aotero@xbiotech.com
512-386-2930
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: XBiotech, Inc via Globenewswire
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Aug 2024 to Sep 2024
XBiotech (NASDAQ:XBIT)
Historical Stock Chart
From Sep 2023 to Sep 2024